JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT financial statements, including revenue, expenses, profit, and loss
The total revenue of 600200 for the last quarter is 732.97 M CNY, and it's 83.51% higher compared to the previous quarter. The net income of Q4 23 is -82.90 M CNY.